TY - JOUR
AU - Nitin Vidyasagar
AU - Samuel R. Bunting
AU - Vineet M. Arora
AU - Mim Ari
A1 - 
AD - Pritzker School of Medicine, University of Chicago, Chicago, IL, US nvidyasa@uchicagomedicine.org; Department of Psychiatry & Behavioral Neuroscience, University of Chicago, Chicago, IL, US ; Department of Medicine, University of Chicago, Chicago, IL, US ; Vidyasagar, Nitin,5841 S Maryland Ave, MC 3077,Chicago,US,60637,Pritzker School of Medicine, University of Chicago,nvidyasa@uchicagomedicine.org
BT - JAMA: Journal of the American Medical Association
C5 - Opioids & Substance Use
CP - 6
DB - APA PsycInfo®
DO - 10.1001/jama.2023.26522
IS - 6
JF - JAMA: Journal of the American Medical Association
LA - English
PY - 2024
SN - 0098-7484, 0098-7484
SP - 524
EP - 526+
ST - Availability of long-acting injectable buprenorphine at substance use treatment facilities in 2021
T1 - Availability of long-acting injectable buprenorphine at substance use treatment facilities in 2021
T2 - JAMA: Journal of the American Medical Association
TI - Availability of long-acting injectable buprenorphine at substance use treatment facilities in 2021
U1 - Opioids & Substance Use
U3 - 10.1001/jama.2023.26522
VL - 331
VO - 0098-7484, 0098-7484
Y1 - 2024
ER -